Advertisement

Topics

EC approves Pfizer’s acute lymphoblastic leukemia treatment Besponsa

19:00 EDT 3 Jul 2017 | Pharmaceutical Technology

The European Commission (EC) has approved Pfizer’s Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL) in the European Union (EU).

Original Article: EC approves Pfizer’s acute lymphoblastic leukemia treatment Besponsa

NEXT ARTICLE

More From BioPortfolio on "EC approves Pfizer’s acute lymphoblastic leukemia treatment Besponsa"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...